BioVentrix announces the 1st Revivent TC™ TransCatheter Ventricular Enhancement procedure for Ischemic Cardiomyopathy treatment in the Netherlands

SAN RAMON, Calif., and NIEUWEGEIN, Netherlands, Nov. 21, 2016 /PRNewswire/ -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced the first clinical use in the Netherlands of its closed-chest Revivent TC™ TransCatheter Ventricular Enhancement System. The Less Invasive Ventricular Enhancement™ or LIVE™ procedure was performed by cardiothoracic surgeon Dr. Patrick Klein, MD and by interventional cardiologist Dr. Pierfrancesco Agostoni, MD at the St. Antonius Hospital in Nieuwegein, The Netherlands.

The device was successfully implanted with four micro-anchor pairs in a 56-year-old male patient suffering from ischemic heart failure.  The procedure reshaped the left ventricle and decreased the Left Ventricular End Systolic Volume Index (LVESVI).  Left Ventricular volume reduction is a common measure of cardiac performance that significantly impacts the short and long-term survival rates. By remodeling the LV to a more normal shape and size, the implant improves pumping efficiency, decreases wall stress, and immediately reverses patient symptoms.

"We are very impressed with the clinical benefits of the Revivent TC system.   The patient achieved a 38% reduction in LVESVI," said Dr. Klein. "The procedure reduces wall stress and reshapes the left ventricle to improve its pumping efficiency.  That is important for treating the underlying cause of heart failure," continued Dr. Klein.

"We are excited to be the first center in the Netherlands to implant the Revivent TC System," added Dr. Agostoni.  "We achieved a sizeable reduction in the patient's left ventricular volume and he will see significant improvement in his symptoms. The LIVE procedure is clearly less invasive and provides an important sense of control when operating on the beating heart," continued Dr. Agostoni.

About BioVentrix and the Revivent TC System

BioVentrix, a privately held medical technology company headquartered in San Ramon, Calif., is focused on developing and commercializing minimally invasive therapies for treating HF.  The company recently received CE mark certification for its closed-chest Revivent TC TransCatheter Ventricular Enhancement System for plication of scar tissue in post-MI, ischemic cardiomyopathy patients. Placement of the Revivent TC System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a catheter-based approach. The anchors are then pulled towards one another, effectively excluding the scarred and non-functioning heart wall. Ventricular volume is immediately reduced as a result of the exclusion, by as much as 30-40 percent¹.

Click here for corporate video with animation

Note: The Revivent TC System is approved for sale in Europe; it is not approved for sale in the United States.

¹Wechsler, A. et al., Clinical benefits twelve months after less invasive ventricular restoration operations without ventriculotomy. Annual meeting of the European Society of Cardio-Thoracic Surgery, 07 Oct. 2013, Vienna, Austria.

Logo - http://photos.prnewswire.com/prnh/20151207/293907LOGO

SOURCE BioVentrix Inc.

Related Links

http://www.bioventrix.com